Talk:Miglustat
| This is the talk page for discussing improvements to the Miglustat article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
It is of interest to the following WikiProjects:
| This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks. | |
| Mid | This article has been rated as Mid-importance on the project's importance scale. | |
| This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine. | |
| Mid | This article has been rated as Mid-importance on the project's importance scale. | |
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Miglustat.
|
|
no archives yet (create) |
|
This page has archives. Sections older than 21 days may be automatically archived by Lowercase sigmabot III when more than 4 sections are present. |
Price
[edit]£4015 for pack of 84! £47.80 per capsule. Most expensive capsule purchased by a children's hospital in the London area. There should perhaps be a mention of the high cost of the drug, can somebody explain why the cost is so high? 82.211.83.9 (talk) 14:17, 22 May 2009 (UTC)
- Developing, manufacturing and distributing a drug that brings benefit for only a few hundred patients world wide explains the high price. Especially developing a drug takes years and pharmaceutical companies have to follow stict protocols imposed by health authorities and requiring costly clinical studies. Once approved and authorized for sale, the money gained serves to pay back the money previously spent during the years of development. 212.27.185.253 (talk) 08:27, 23 April 2010 (UTC)
- At our children's hospice we have provided suport for a small number of children who have been prescribed this medication. A number of them have had diarrhoea that has responded reasonably well to a lactose free diet. I think this would be worth a mention on this page. 217.41.3.106 (talk) 15:37, 5 March 2013 (UTC)
External links modified (January 2018)
[edit]Hello fellow Wikipedians,
I have just modified one external link on Miglustat. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
- Added archive https://web.archive.org/web/20140903105602/http://www.pharmatimes.com/article/10-03-10/FDA_rejects_Actelion_s_Zavesca_for_rare_NP-C_disease.aspx to http://www.pharmatimes.com/article/10-03-10/FDA_rejects_Actelion_s_Zavesca_for_rare_NP-C_disease.aspx
- Added
{{dead link}}tag to http://www.chicagotribune.com/health/sns-rt-us-fda-gaucherbre8401jz-20120501,0,5155428.story
When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.
This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).
- If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
- If you found an error with any archives or the URLs themselves, you can fix them with this tool.
Cheers.—InternetArchiveBot (Report bug) 22:50, 29 January 2018 (UTC)
Mechanism of Action
[edit]As (correctly) stated under “Chemistry”, “Miglustat is an iminosugar” of glucose, i.e., the O (oxygen) in the sugar ring is replaced by an N (nitrogen). With many enzymes that use glucose (not only glucocerebrosidase), it binds the active side binding glucose, but the enzyme then cannot act, resulting in a reversible inhibition. Other enzyme affected u alpha-galactosidases A (α-GalA), which causes the known gastrointestinal side effects (diarrhea, …). Kmwittko Reference: https://www.ema.europa.eu/en/documents/scientific-discussion/zavesca-epar-scientific-discussion_en.pdf (talk) 19:45, 30 April 2023 (UTC)